A Phase 1 interventional study of Deucravacitinib and Famotidine in Healthy Participants, sponsored by Bristol-Myers Squibb. Completed at 2 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-11.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the drug levels of deucravacitinib after oral administration in healthy participants.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit: www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Deucravacitinib
Drug: Deucravacitinib
Drug: Deucravacitinib · Drug: Famotidine
Drug: Deucravacitinib
Specified dose on specified days
Also known as: BMS-986165
Specified dose on specified days
Also known as: Pepcid
Maximum Observed Plasma Concentration (Cmax) of deucravacitinib
Time frame: Up to 7 days
Area Under the Concentration-time Curve from time 0 to 24 hours postdose (AUC(0-24)) of deucravacitinib
Time frame: Up to 7 days
Concentration at 24 hours of post-morning dose on Day 1 and Day 7 (C24) of deucravacitinib
Time frame: Up to 7 days
Incidence of non-serious Adverse Events (AEs)
Time frame: Up to 18 days
Incidence of Serious Adverse Events (SAEs)
Time frame: Up to 30 days post discontinuation of dosing or participant's participation in the study
Incidence of clinically significant changes in clinical laboratory values: Hematology tests
Time frame: Up to 11 days
Incidence of clinically significant changes in clinical laboratory values: Chemistry tests
Time frame: Up to 11 days
Incidence of clinically significant changes in clinical laboratory values: Urinalysis tests
Time frame: Up to 11 days
Incidence of clinically significant changes in vital signs: Body temperature
Time frame: Up to 11 days
Incidence of clinically significant changes in vital signs: Respiratory rate
Time frame: Up to 11 days
Incidence of clinically significant changes in vital signs: Blood pressure
Time frame: Up to 11 days
Incidence of clinically significant changes in vital signs: Heart rate
Time frame: Up to 11 days
Incidence of clinically significant changes in electrocardiogram (ECG) parameters: PR interval
PR interval is the time from the onset of the P wave to the start of the QRS complex
Time frame: Up to 11 days
Incidence of clinically significant changes in ECG parameters: QRS
QRS can be defined as the electrical impulse as it spreads through the ventricles, indicating ventricular depolarization
Time frame: Up to 11 days
Incidence of clinically significant changes in ECG parameters: QT interval
The QT interval is the time from the start of the Q wave to the end of the T wave
Time frame: Up to 11 days
Incidence of clinically significant changes in ECG parameters: QTcF
QTcF = Corrected QT interval using the Fridericia formula. QT interval is the time from the start of the Q wave to the end of the T wave
Time frame: Up to 11 days
Ran from Jul 2021 to primary completion in Jan 2022, 5 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Deucravacitinib